[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100517615":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":30,"responsibleParty":113,"collaborators":115,"id":119,"slug":20,"hasResults":120,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":120,"sex":126,"minAge":127,"maxAge":20,"enrollmentInfo":128,"targetDuration":20,"studyType":131,"phases":132,"briefSummary":134,"conditions":135,"keywords":137,"overallStatus":33,"whyStopped":20,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":153},{"fullName":5,"class":6},"Stereotaxis","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment","EXPERIMENTAL","Magnetic Interventional Ablation Catheter (MAGiC™)",[13],"Device: MAGiC™",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","MAGiC™","Robotic magnetic radiofrequency (RF) ablation catheter",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Betsy Lowry","STUDY_DIRECTOR",[26],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","9737236613","betsy.lowry@stereotaxis.com",[31,52,70,92],{"facility":32,"status":33,"city":34,"state":20,"zip":20,"country":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Rigshospitalet, University of Copenhagen","RECRUITING","Copenhagen","Denmark",{"type":37,"coordinates":38},"Point",[39,40],12.56553,55.67594,{"lat":40,"lon":39},[43,46,49],{"name":44,"role":27,"phone":20,"phoneExt":20,"email":45},"Aslaug Karlsdóttir","aslaug.thora.karlsdottir@regionh.dk",{"name":47,"role":27,"phone":20,"phoneExt":20,"email":48},"Lærke Bjerregaard Heidum","laerke.bjerregaard.heidum@regionh.dk",{"name":50,"role":51,"phone":20,"phoneExt":20,"email":20},"Peter Jacobsen, MD","PRINCIPAL_INVESTIGATOR",{"facility":53,"status":33,"city":54,"state":20,"zip":20,"country":55,"cosmosGeoPoint":56,"geoPoint":60,"contacts":61},"Vilniaus universiteto ligoninė Santaros klinikos","Vilnius","Lithuania",{"type":37,"coordinates":57},[58,59],25.2798,54.68916,{"lat":59,"lon":58},[62,65,68],{"name":63,"role":27,"phone":20,"phoneExt":20,"email":64},"Kridtina Ščerbakovaitė","Kristina.Scerbakovaite@santa.lt",{"name":66,"role":27,"phone":20,"phoneExt":20,"email":67},"Jūratė Barysienė","Jurate.Barysiene@santa.lt",{"name":69,"role":51,"phone":20,"phoneExt":20,"email":20},"Gediminas Račkauskas, MD",{"facility":71,"status":72,"city":73,"state":20,"zip":74,"country":75,"cosmosGeoPoint":76,"geoPoint":80,"contacts":81},"Erasmus Medical Center","NOT_YET_RECRUITING","Rotterdam","3015 GD","Netherlands",{"type":37,"coordinates":77},[78,79],4.47917,51.9225,{"lat":79,"lon":78},[82,86,90],{"name":83,"role":27,"phone":84,"phoneExt":20,"email":85},"Elco van der Heide","31630605231","e.vanderheide@erasmusmc.nl",{"name":87,"role":27,"phone":88,"phoneExt":20,"email":89},"Astrid Coenen-Vrijhoeven, RN","31614633780","j.coenen-vrijhoeven@erasmusmc.nl",{"name":91,"role":51,"phone":20,"phoneExt":20,"email":20},"Sing-Chien Yap, MD, PhD",{"facility":93,"status":72,"city":94,"state":20,"zip":95,"country":96,"cosmosGeoPoint":97,"geoPoint":101,"contacts":102},"National Institute of Cardiology","Warsaw","04-628","Poland",{"type":37,"coordinates":98},[99,100],21.01178,52.22977,{"lat":100,"lon":99},[103,107,111],{"name":104,"role":27,"phone":105,"phoneExt":20,"email":106},"Kinga Krajenska Piestrzynska, BS","+68699355636","kkrajenska@ikard.pl",{"name":108,"role":27,"phone":109,"phoneExt":20,"email":110},"Ewa Swierzynska, MSc, PhD","+68507609972","eswierzynska@ikard.pl",{"name":112,"role":51,"phone":20,"phoneExt":20,"email":20},"Lukasz Szumowski, MD, PhD",{"type":114,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[116],{"name":117,"class":118},"Osypka AG","UNKNOWN","100517615",false,"NCT06019845","The MAGiC™ Cardiac Ablation European Study","The MAGiC™ Cardiac Ablation Feasibility Study \u002F Pomt Market Clinical Follow-Up","MAGiC-FESTPMCF","Inclusion Criteria:\n\n* Adult (aged 18 or older at time of consent);\n* Eligible for ablation procedures of an atrial or ventricular arrhythmia per European Heart Rhythm Association (EHRA) guidelines, lctrocardiographically documented within 12 months \\[rior to enrollment;\n* Able to be safely exposed to magnetic fields;\n* Willing and capable to attend scheduled follow up visits at the study site for the study duration (up to 12 months)\n* Willing and able to provide informed consent.\n\nExclusion Criteria:\n\n* Unable to be safely exposed to magnetic fields due to Magnetic Resonance Imaging Unsafe device (implanted device or device that cannot be safely removed for the procedure)\n* Unable to remain comfortable or hemodynamically stable in the supine position for an extended period of time\n* Weight exceeding 200 kg (the weight limit of the table)\n* Women of childbearing age who are pregnant or who plan to become pregnant within the course of their participation in the study. Must have a negative pregnancy test.\n* Presence of intracardiac thrombus within 12 weeks prior to enrollment\n* Where MAGiC would need to cross a prosthetic valve\n* Use of MAGiC in the coronary arteries\n* A history of sensitivity to foreign objects or extreme allergies\n* Acute illness or active systemic infection\n* Histological or anatomical abnormalities that may lead to post-operative complications including diminished resistance to infection\n* Unable to receive heparin or an acceptable alternative to achieve adequate anticoagulation\n* Acute myocardial infarct (within the previous 6 weeks)\n* Recent cardiac surgery (within the previous 8 weeks)\n* Unstable angina at the time of enrollment\n* History of embolism (cerebrovascular accident, transient ischemic attack, systemic embolism) in the previous 30 days\n* Previous cardiac ablation within the previous 30 days\n* EP ablation within the previous 6 weeks.\n* Life expectancy \\\u003C12 months per the physician opinion.\n* Currently or in the 30 days prior to consent, participation in an interventional clinical trial\n* Significant uncontrolled or unstable medical problems which, in the opinion of the Investigator, would preclude enrollment in and completion of the study (limitation on survival).\n* Any reason or condition that, in the judgement of the investigator, makes the patient ineligible for the investigation.","ALL","18 Years",{"count":129,"type":130},150,"ESTIMATED","INTERVENTIONAL",[133],"NA","The purpose of the first phase of this feasibility study is to gather safety and performance data on MAGiC to support European marketing approval.\n\nThe purpose of MAGiC-FEST PMCF Study is to collect safety and performance data with MAGiC to meet ongoing regulatory obligations.",[136],"Arrhythmias, Cardiac",[138,139,140,141,142,143],"Atrial Fibrillation","Atrial Flutter","Ventricular Tachycardia","Supraventricular Tachycardia","Ablation","Premature Ventricular Contractions","2026-04-28",{"date":146,"type":147},"2026-05-04","ACTUAL",{"date":149,"type":147},"2024-01-02",{"date":151,"type":130},"2028-12-31",{"name":5,"class":6},4]